Pressure BioSciences (OTCQB: PBIO), a leader in the development and sale of broadly enabling, pressure-based instruments, consumables, and platform technology solutions to the worldwide biotechnology, biotherapeutics, nutraceuticals, cosmetics, agriculture, and food & beverage industries, has signed a letter of intent (“LOI”) to purchase to purchase the assets of an internationally based developer and supplier of organically natural, eco-friendly agrochemicals. The company noted that the acquisition enables PBIO to enter the agrochemical market with alternatives to synthetic pesticides and fertilizers. The acquisition is expected to be complete in four weeks as PBIO anticipates initiating announcements regarding the acquired assets, global distributorship arrangements, UST enhancement of key products, purchase order receipts/product shipments, and the expected accretive financial impact of the acquisition. “As previously announced, upon completion, this acquisition of assets will establish PBI with a portfolio of respected brand names in the eco-friendly agrochemicals market, with unique and effective proprietary formulations, advantageous manufacturer relationships, trademarks, intellectual property, registrations and licenses, and access to distributor and end-customer relationships worldwide,” said Pressure BioSciences president and CEO Richard T. Schumacher in the press release. “We expect these assets to be accretive, driving significant new revenues and profitability by Q4 2021 and substantially in 2022 and beyond. . . . While the acquired assets are expected to be dramatically impactful, we expect that our UST nanoemulsions technology platform will propel a major improvement in the economics and effectiveness of agrochemicals. We are looking forward to the opportunity to leverage the UST technology platform within a diverse line of next-generation, eco-friendly agrochemicals that fall into two of the hottest growth segments in agricultural production worldwide: organic foods and environmental sustainability.”
To view the full press release, visit https://ibn.fm/2uFuA
About Pressure BioSciences Inc.
Pressure BioSciences is a leader in the development and sale of innovative, broadly enabling, pressure-based solutions for the worldwide life sciences and other industries. PBIO’s products are based on the unique properties of both constant (i.e., static) and alternating (i.e., pressure cycling technology, or “PCT”) hydrostatic pressure. PCT is a patented-enabling technology platform that uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to safely and reproducibly control bio-molecular interactions (e.g., cell lysis, biomolecule extraction). The company’s primary focus is on the development of PCT-based products for biomarker and target discovery, drug design and development, biotherapeutics characterization and quality control, soil and plant biology, forensics and counter-bioterror applications. Additionally, major new market opportunities have emerged in the use of PBIO’s pressure-based technologies in the following areas: (1) the use of its recently acquired, patented technology from BaroFold Inc. (the “BaroFold” technology) to allow entry into the bio-pharma contract services sector, and (2) the use of its recently patented, scalable, high-efficiency, pressure-based Ultra Shear Technology (“UST”) platform to (i) create stable nanoemulsions of otherwise immiscible fluids (e.g., oils and water) and to (ii) prepare higher quality, homogenized, extended shelf-life or room-temperature, stable, low-acid liquid foods that cannot be effectively preserved using existing nonthermal technologies. For more information, visit the company website at www.PressureBioSciences.com.
NOTE TO INVESTORS: The latest news and updates relating to PBIO are available in the company’s newsroom at http://ibn.fm/PBIO
About MissionIRNewsBreaks
MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.
MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com
Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html
